Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Literature
1.
Tahara T, Tahara S, Tuskamoto T, et al. Telomere length in the gastric mucosa after Helicobacter pylori eradication and its potential role in the gastric carcinogenesis. Clin Exp Med. 2017. doi:10.​1007/​s10238-017-0458-1.
2.
Lee H, Jin JD, La BM, et al. TERT promoter mutation, telomere length, and TERT expression in gastric cancer. Int J Clin Exp Pathol. 2016;9:1758–63.
3.
Lee H, Hwang IS, Choi IJ, et al. Are PIK3CA mutation and amplification associated with clinicopathological characteristics of gastric cancer? Asian Pac J Cancer Prev. 2015;16:4493–6.CrossRefPubMed
4.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
Metadata
Title
Association between telomere length and PIK3CA amplification in gastric cancer
Authors
Yu-Ran Heo
Jae-Ho Lee
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0465-2

Other articles of this Issue 1/2018

Clinical and Experimental Medicine 1/2018 Go to the issue

Review Article

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Original Article

Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis

Original Article

Telomere length in the gastric mucosa after Helicobacter pylori eradication and its potential role in the gastric carcinogenesis

Original Article

Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure

Original Article

Age-related alterations of the CD19 complex and memory B cells in children with Down syndrome

Original Article

SATB2 suppresses non-small cell lung cancer invasiveness by G9a
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits